Cargando…

Genetic deletion of soluble epoxide hydrolase delays the progression of Alzheimer’s disease

BACKGROUND: Soluble epoxide hydrolase (sEH) is a bifunctional enzyme with COOH-terminal hydrolase and NH2-terminal lipid phosphatase activities. It is expressed in various cell types in the brain and is involved in the pathogenesis of inflammatory and neurodegenerative diseases. Alzheimer’s disease...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Hsueh-Te, Lee, Kuan-I, Chen, Chia-Hui, Lee, Tzong-Shyuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6916033/
https://www.ncbi.nlm.nih.gov/pubmed/31847859
http://dx.doi.org/10.1186/s12974-019-1635-9
_version_ 1783480147817529344
author Lee, Hsueh-Te
Lee, Kuan-I
Chen, Chia-Hui
Lee, Tzong-Shyuan
author_facet Lee, Hsueh-Te
Lee, Kuan-I
Chen, Chia-Hui
Lee, Tzong-Shyuan
author_sort Lee, Hsueh-Te
collection PubMed
description BACKGROUND: Soluble epoxide hydrolase (sEH) is a bifunctional enzyme with COOH-terminal hydrolase and NH2-terminal lipid phosphatase activities. It is expressed in various cell types in the brain and is involved in the pathogenesis of inflammatory and neurodegenerative diseases. Alzheimer’s disease (AD) is a progressive neuroinflammatory and neurodegenerative disease. However, the pathological significance of sEH and underlying molecular mechanism in AD remain unclear. METHODS: To examine the role of sEH in pathogenesis of AD, we used wild-type (WT) mice, soluble epoxide hydrolase deficient (sEH(−/−)) and two mouse models of AD, including amyloid precursor protein (APP)/presenilin 1 (PS1) transgenic (APP/PS1 Tg) and APP/PS1 Tg/sEH(−/−) mice. Western blotting analysis and immunohistochemistry assay were performed to evaluate the protein expression. Locomotion, nesting building ability, Y-maze, and Morris water maze tests were conducted to study mouse behavior. The levels of interleukin (IL)-1β, IL-4, IL-6, and IL-10 and the activities of NF-κB and nuclear factor of activated T cells (NFAT) were measured by commercial assay kits. The quantitative protein level profiling in the brain lysate was analyzed using LC-MS/MS approaches. RESULTS: We demonstrated that the level of sEH was increased in the brain and predominantly appeared in hippocampal astrocytes of APP/PS1 Tg mice. Genetic ablation of sEH in APP/PS1 Tg mice delayed the progression of AD as evidenced by the alleviation in behavior outcomes and Aβ plaque deposition. In addition, loss of the function of sEH in APP/PS1 Tg mice increased astrogliosis and the production of astrocyte-derived anti-inflammatory cytokines including IL-1β, IL-4, and IL-10, as well as the activity of NF-kB and NFAT. Moreover, analysis of gene ontology in the AD brain revealed that important signaling pathways and processes related to AD pathogenesis such as translational regulation, oxidative stress, cytoskeleton reorganization, and small GTPase signal transduction were altered in APP/PS1 Tg/sEH(−/−) mice compared with APP/PS1 Tg mice. CONCLUSION: Our results suggest that sEH is a crucial regulator in the progression of AD and might be a potential therapeutic target for the treatment of AD.
format Online
Article
Text
id pubmed-6916033
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-69160332019-12-30 Genetic deletion of soluble epoxide hydrolase delays the progression of Alzheimer’s disease Lee, Hsueh-Te Lee, Kuan-I Chen, Chia-Hui Lee, Tzong-Shyuan J Neuroinflammation Research BACKGROUND: Soluble epoxide hydrolase (sEH) is a bifunctional enzyme with COOH-terminal hydrolase and NH2-terminal lipid phosphatase activities. It is expressed in various cell types in the brain and is involved in the pathogenesis of inflammatory and neurodegenerative diseases. Alzheimer’s disease (AD) is a progressive neuroinflammatory and neurodegenerative disease. However, the pathological significance of sEH and underlying molecular mechanism in AD remain unclear. METHODS: To examine the role of sEH in pathogenesis of AD, we used wild-type (WT) mice, soluble epoxide hydrolase deficient (sEH(−/−)) and two mouse models of AD, including amyloid precursor protein (APP)/presenilin 1 (PS1) transgenic (APP/PS1 Tg) and APP/PS1 Tg/sEH(−/−) mice. Western blotting analysis and immunohistochemistry assay were performed to evaluate the protein expression. Locomotion, nesting building ability, Y-maze, and Morris water maze tests were conducted to study mouse behavior. The levels of interleukin (IL)-1β, IL-4, IL-6, and IL-10 and the activities of NF-κB and nuclear factor of activated T cells (NFAT) were measured by commercial assay kits. The quantitative protein level profiling in the brain lysate was analyzed using LC-MS/MS approaches. RESULTS: We demonstrated that the level of sEH was increased in the brain and predominantly appeared in hippocampal astrocytes of APP/PS1 Tg mice. Genetic ablation of sEH in APP/PS1 Tg mice delayed the progression of AD as evidenced by the alleviation in behavior outcomes and Aβ plaque deposition. In addition, loss of the function of sEH in APP/PS1 Tg mice increased astrogliosis and the production of astrocyte-derived anti-inflammatory cytokines including IL-1β, IL-4, and IL-10, as well as the activity of NF-kB and NFAT. Moreover, analysis of gene ontology in the AD brain revealed that important signaling pathways and processes related to AD pathogenesis such as translational regulation, oxidative stress, cytoskeleton reorganization, and small GTPase signal transduction were altered in APP/PS1 Tg/sEH(−/−) mice compared with APP/PS1 Tg mice. CONCLUSION: Our results suggest that sEH is a crucial regulator in the progression of AD and might be a potential therapeutic target for the treatment of AD. BioMed Central 2019-12-17 /pmc/articles/PMC6916033/ /pubmed/31847859 http://dx.doi.org/10.1186/s12974-019-1635-9 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Lee, Hsueh-Te
Lee, Kuan-I
Chen, Chia-Hui
Lee, Tzong-Shyuan
Genetic deletion of soluble epoxide hydrolase delays the progression of Alzheimer’s disease
title Genetic deletion of soluble epoxide hydrolase delays the progression of Alzheimer’s disease
title_full Genetic deletion of soluble epoxide hydrolase delays the progression of Alzheimer’s disease
title_fullStr Genetic deletion of soluble epoxide hydrolase delays the progression of Alzheimer’s disease
title_full_unstemmed Genetic deletion of soluble epoxide hydrolase delays the progression of Alzheimer’s disease
title_short Genetic deletion of soluble epoxide hydrolase delays the progression of Alzheimer’s disease
title_sort genetic deletion of soluble epoxide hydrolase delays the progression of alzheimer’s disease
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6916033/
https://www.ncbi.nlm.nih.gov/pubmed/31847859
http://dx.doi.org/10.1186/s12974-019-1635-9
work_keys_str_mv AT leehsuehte geneticdeletionofsolubleepoxidehydrolasedelaystheprogressionofalzheimersdisease
AT leekuani geneticdeletionofsolubleepoxidehydrolasedelaystheprogressionofalzheimersdisease
AT chenchiahui geneticdeletionofsolubleepoxidehydrolasedelaystheprogressionofalzheimersdisease
AT leetzongshyuan geneticdeletionofsolubleepoxidehydrolasedelaystheprogressionofalzheimersdisease